Immatics appoints Dr Rainer Kramer as Chief Business Officer
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr Rainer Kramer as Chief Business Officer (CBO) with immediate effect.
In this newly created role, Dr Kramer will lead Immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.
Dr Kramer has many years of business development experience within the pharmaceutical industry. He joins from Signature Diagnostics, an oncology diagnostics company where he was CBO. Before that, he was Vice President Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities, and played a key role in the sale of the Company to Shire in 2008. Before joining Jerini, he held various business development and research positions at MorphoSys AG, Martinsried, and Amgen Inc. Dr Kramer holds a Diploma in Molecular Biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.
“Rainer’s appointment is a further important step in advancing our business strategy aimed at maximizing the potential of our TUMAP-based therapeutic cancer vaccine pipeline”, said Paul Higham, CEO of Immatics. “The positive clinical results that we have already generated with our lead products IMA901, for advanced renal cancer, and IMA910, for advanced colorectal cancer, highlight our potential to make a real difference to the management of these difficult to treat cancers. Rainer’s strong business and deal-making experience will be a great asset as we seek partners where appropriate to help us to progress our vaccine candidates to market.”
Rainer Kramer said: “The impressive data with IMA901 and IMA910 confirm the tremendous potential of this novel class of therapeutic vaccines. I am delighted to be joining immatics at such an exciting time and look forward to making a significant contribution to the successful implementation of the Company’s corporate strategy, which is expected to deliver significant shareholder value and much improved treatment options for cancer patients.”